Floatz logo

17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE

Sézary Syndrome

Elorac, Inc.Small moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Sézary Syndrome cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BB
PREDNISONE TABLETS
Shanghai Jiao Tong University School of Medicine
Phase 4BB
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BB
CYCLOSPORIN A
Ohio State University Comprehensive Cancer Center
Phase 2BB
Denileukin Diftitox
Eisai Inc.
Phase 4B

View all 40 →

Same molecule, other indications

17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE is also rated in:

Low Back PainDormant
BBB
Indicative ·
74 / 100
View asset →
PainDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic OsteoarthritisDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →